

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

Date: (Filing No. H-)

CRIMINAL JUSTICE AND PUBLIC SAFETY

Reproduced and distributed under the direction of the Clerk of the House.

**STATE OF MAINE
HOUSE OF REPRESENTATIVES
126TH LEGISLATURE
FIRST REGULAR SESSION**

COMMITTEE AMENDMENT “ ” to H.P. 453, L.D. 661, Bill, “An Act To Prohibit Sale or Possession of Synthetic Cannabinoids”

Amend the bill by striking out everything after the enacting clause and before the summary and inserting the following:

Sec. 1. 17-A MRSA §1101, sub-§1-A, as enacted by PL 2011, c. 428, §1 and affected by §9, is repealed.

Sec. 2. 17-A MRSA §1101, sub-§1-B, as enacted by PL 2011, c. 428, §2 and affected by §9, is repealed.

Sec. 3. 17-A MRSA §1101, sub-§3-A, as enacted by PL 2011, c. 428, §3 and affected by §9, is repealed.

Sec. 4. 17-A MRSA §1101, sub-§3-B, as enacted by PL 2011, c. 428, §4 and affected by §9, is repealed.

Sec. 5. 17-A MRSA §1102, sub-§4, ¶F, as enacted by PL 2011, c. 428, §7 and affected by §9, is repealed.

Sec. 6. 17-A MRSA §1102, sub-§4, ¶G is enacted to read:

G. Synthetic cannabinoids, including:

(1) Tetrahydrocannabinols that are naturally contained in a plant of the genus cannabis or a cannabis plant, as well as synthetic equivalents of the substances contained in the cannabis plant or in the resinous extractives of cannabis or synthetic substances, derivatives and their isomers with similar chemical structure and pharmacological activity, including the following:

- (a) Delta-1 cis or trans tetrahydrocannabinol and their optical isomers;
- (b) Delta-6 cis or trans tetrahydrocannabinol and their optical isomers; or
- (c) Delta-3,4 cis or trans tetrahydrocannabinol and their optical isomers;

COMMITTEE AMENDMENT

1 (2) Naphthoylindoles, including any compound containing a 3-(1-
2 naphthoyl)indole structure with substitution at the nitrogen atom of the indole
3 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
4 methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not
5 further substituted in the indole ring to any extent and whether or not substituted
6 in the naphthyl ring to any extent, including the following:

7 (a) 1-Pentyl-3-(1-naphthoyl)indole or JWH-018 or AM-678;

8 (b) 1-Butyl-3-(1-naphthoyl)indole or JWH-073;

9 (c) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole or JWH-081;

10 (d) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole or JWH-200;

11 (e) 1-Propyl-2-methyl-3-(1-naphthoyl)indole or JWH-015;

12 (f) 1-Hexyl-3-(1-naphthoyl)indole or JWH-019;

13 (g) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole or JWH-122;

14 (h) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole or JWH-210;

15 (i) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole or JWH-398; or

16 (j) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole or AM-2201;

17 (3) Naphthylmethylindoles, including any compound containing a H-indol-3-yl-
18 (1-naphthyl)methane structure with substitution at the nitrogen atom of the indole
19 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
20 methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not
21 further substituted in the indole ring to any extent and whether or not substituted
22 in the naphthyl ring to any extent, including the following:

23 (a) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane or JWH-175; or

24 (b) 1-Pentyl-1H-3-yl-(4-methyl-1-naphthyl)methane or JWH-184;

25 (4) Naphthoylpyrroles, including any compound containing a 3-(1-
26 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole
27 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-
28 morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to
29 any extent and whether or not substituted in the naphthyl ring to any extent,
30 including (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone or
31 JWH-307;

32 (5) Naphthylideneindenes or naphthylmethylindenes, including any compound
33 containing a naphthylideneindene structure with substitution at the 3-position of
34 the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
35 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or
36 not further substituted in the indene ring to any extent and whether or not
37 substituted in the naphthyl ring to any extent, including E-1-[1-(1-
38 Naphthalenylmethylene)-1H-inden-3-yl]pentane or JWH-176;

1 (6) Phenylacetylindoles, including any compound containing a 3-
2 phenylacetylindole structure with substitution at the nitrogen atom of the indole
3 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
4 methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not
5 further substituted in the indole ring to any extent and whether or not substituted
6 in the phenyl ring to any extent, including the following:

7 (a) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole or RCS-8;

8 (b) 1-Pentyl-3-(2-methoxyphenylacetyl)indole or JWH-250;

9 (c) 1-Pentyl-3-(2-methylphenylacetyl)indole or JWH-251; or

10 (d) 1-Pentyl-3-(2-chlorophenylacetyl)indole, or JWH-203;

11 (7) Cyclohexylphenols, including any compound containing a 2-(3-
12 hydroxycyclohexyl)phenol structure with substitution at the 5-position of the
13 phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
14 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or
15 not substituted in the cyclohexyl ring to any extent, and their isomers with similar
16 chemical structure and pharmacological activity, including the following:

17 (a) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol or CP
18 47,497;

19 (b) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol or
20 Cannabicyclohexanol or CP 47,497-C8 homologue; or

21 (c) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
22 hydroxypropyl)cyclohexyl]-phenol or CP 55,490;

23 (8) Benzoylindoles, including any compound containing a 3-(benzoyl)indole
24 structure with substitution at the nitrogen atom of the indole ring by an alkyl,
25 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
26 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
27 substituted in the indole ring to any extent and whether or not substituted in the
28 phenyl ring to any extent, including the following:

29 (a) 1-Pentyl-3-(4-methoxybenzoyl)indole or RCS-4;

30 (b) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole or AM-694; or

31 (c) (4-Methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-
32 yl]methanone or WIN-48,098 or Pravadoline; and

33 (9) The following other unclassified synthetic cannabinoids:

34 (a) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-
35 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol or HU-210;

36 (b) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-
37 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol or Dexanabinol or HU-211;

